Targeting the bacteria–host interface

References

• Hayes CS, Aoki SK, Low DA. Bacterial contact-dependent delivery systems. Annu Rev Genet 2010; 44:71 - 90; http://dx.doi.org/10.1146/annurev.genet.42.110807.091449; PMID: 21047256
   PubMed Web of Science ®Google Scholar
• Winnen B, Schlumberger MC, Sturm A, Schüpbach K, Siebenmann S, Jenny P, et al. Hierarchical effector protein transport by the Salmonella Typhimurium SPI-1 type III secretion system. PLoS One 2008; 3:e2178; http://dx.doi.org/10.1371/journal.pone.0002178; PMID: 18478101
   PubMedGoogle Scholar
• Schlumberger MC, Müller AJ, Ehrbar K, Winnen B, Duss I, Stecher B, et al. Real-time imaging of type III secretion: Salmonella SipA injection into host cells. Proc Natl Acad Sci U S A 2005; 102:12548 - 53; http://dx.doi.org/10.1073/pnas.0503407102; PMID: 16107539
   PubMed Web of Science ®Google Scholar
• Zhou D, Galán J. Salmonella entry into host cells: the work in concert of type III secreted effector proteins. Microbes Infect 2001; 3:1293 - 8; http://dx.doi.org/10.1016/S1286-4579(01)01489-7; PMID: 11755417
   PubMed Web of Science ®Google Scholar
• Neunuebel MR, Chen Y, Gaspar AH, Backlund PS Jr., Yergey A, Machner MP. De-AMPylation of the small GTPase Rab1 by the pathogen Legionella pneumophila. Science 2011; 333:453 - 6; http://dx.doi.org/10.1126/science.1207193; PMID: 21680813
   PubMed Web of Science ®Google Scholar
• Krachler AM, Ham H, Orth K. Outer membrane adhesion factor multivalent adhesion molecule 7 initiates host cell binding during infection by gram-negative pathogens. Proc Natl Acad Sci U S A 2011; 108:11614 - 9; http://dx.doi.org/10.1073/pnas.1102360108; PMID: 21709226
   PubMed Web of Science ®Google Scholar
• Kim YR, Lee SE, Kook H, Yeom JA, Na HS, Kim SY, et al. Vibrio vulnificus RTX toxin kills host cells only after contact of the bacteria with host cells. Cell Microbiol 2008; 10:848 - 62; http://dx.doi.org/10.1111/j.1462-5822.2007.01088.x; PMID: 18005241
   PubMed Web of Science ®Google Scholar
• Yuehuei H. An, Richard B. Dickinson, Doyle RJ. Molecular Basis of Bacterial Adhesion. In: Yuehuei H. An, Friedman RJ, eds. Handbook of Bacterial Adhesion Principles, Methods, and Applications: Springer, 2000:29-41.
   Google Scholar
• Anderson BN, Ding AM, Nilsson LM, Kusuma K, Tchesnokova V, Vogel V, et al. Weak rolling adhesion enhances bacterial surface colonization. J Bacteriol 2007; 189:1794 - 802; http://dx.doi.org/10.1128/JB.00899-06; PMID: 17189376
   PubMed Web of Science ®Google Scholar
• Breines DM, Burnham JC. Modulation of Escherichia coli type 1 fimbrial expression and adherence to uroepithelial cells following exposure of logarithmic phase cells to quinolones at subinhibitory concentrations. J Antimicrob Chemother 1994; 34:205 - 21; http://dx.doi.org/10.1093/jac/34.2.205; PMID: 7814281
   PubMed Web of Science ®Google Scholar
• Dal SM, Bovio C, Culici M, Braga PC. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res 2002; 28:75 - 82; PMID: 12224380
   PubMedGoogle Scholar
• Wojnicz D, Jankowski S. Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains. Int J Antimicrob Agents 2007; 29:700 - 4; http://dx.doi.org/10.1016/j.ijantimicag.2007.01.007; PMID: 17382520
   PubMed Web of Science ®Google Scholar
• Chen SL, Hung CS, Xu J, Reigstad CS, Magrini V, Sabo A, et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A 2006; 103:5977 - 82; http://dx.doi.org/10.1073/pnas.0600938103; PMID: 16585510
   PubMed Web of Science ®Google Scholar
• Svensson A, Larsson A, Emtenäs H, Hedenström M, Fex T, Hultgren SJ, et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2001; 2:915 - 8; http://dx.doi.org/10.1002/1439-7633(20011203)2:12<915::AID-CBIC915>3.0.CO;2-M; PMID: 11948880
   PubMed Web of Science ®Google Scholar
• Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A 2006; 103:17897 - 902; http://dx.doi.org/10.1073/pnas.0606795103; PMID: 17098869
   PubMed Web of Science ®Google Scholar
• Chorell E, Pinkner JS, Phan G, Edvinsson S, Buelens F, Remaut H, et al. Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem 2010; 53:5690 - 5; http://dx.doi.org/10.1021/jm100470t; PMID: 20586493
   PubMed Web of Science ®Google Scholar
• Chorell E, Pinkner JS, Bengtsson C, Banchelin TS, Edvinsson S, Linusson A, et al. Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study. Bioorg Med Chem 2012; 20:3128 - 42; http://dx.doi.org/10.1016/j.bmc.2012.01.048; PMID: 22464688
   PubMed Web of Science ®Google Scholar
• Chorell E, Pinkner JS, Bengtsson C, Edvinsson S, Cusumano CK, Rosenbaum E, et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chemistry 2012; 18:4522 - 32; http://dx.doi.org/10.1002/chem.201103936; PMID: 22431310
   PubMed Web of Science ®Google Scholar
• Cho JA, Chinnapen DJ, Aamar E, Te Welscher YM, Lencer WI, Massol R. Insights on the trafficking and retro-translocation of glycosphingolipid-binding bacterial toxins. Front Cell Infect Microbiol 2012; 2:51; http://dx.doi.org/10.3389/fcimb.2012.00051; PMID: 22919642
   PubMed Web of Science ®Google Scholar
• Hartlova A, Cerveny L, Hubalek M, Krocova Z, Stulik J. Membrane rafts: a potential gateway for bacterial entry into host cells. Microbiol Immunol 2010; 54:237 - 45; http://dx.doi.org/10.1111/j.1348-0421.2010.00198.x; PMID: 20377752
   PubMed Web of Science ®Google Scholar
• Radin NS. Preventing the binding of pathogens to the host by controlling sphingolipid metabolism. Microbes Infect 2006; 8:938 - 45; http://dx.doi.org/10.1016/j.micinf.2005.09.005; PMID: 16460984
   PubMed Web of Science ®Google Scholar
• Svensson M, Frendeus B, Butters T, Platt F, Dwek R, Svanborg C. Glycolipid depletion in antimicrobial therapy. Mol Microbiol 2003; 47:453 - 61; http://dx.doi.org/10.1046/j.1365-2958.2003.03306.x; PMID: 12519195
   PubMed Web of Science ®Google Scholar
• Svensson M, Platt FM, Svanborg C. Glycolipid receptor depletion as an approach to specific antimicrobial therapy. FEMS Microbiol Lett 2006; 258:1 - 8; http://dx.doi.org/10.1111/j.1574-6968.2006.00175.x; PMID: 16630247
   PubMed Web of Science ®Google Scholar
• Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005; 27:1215 - 27; http://dx.doi.org/10.1016/j.clinthera.2005.08.004; PMID: 16199246
   PubMed Web of Science ®Google Scholar
• Margalit M, Ash N, Zimran A, Halkin H. Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher’s disease. Postgrad Med J 2002; 78:564 - 5; http://dx.doi.org/10.1136/pmj.78.923.564; PMID: 12357022
   PubMed Web of Science ®Google Scholar
• Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006; 1760:527 - 37; http://dx.doi.org/10.1016/j.bbagen.2005.12.008; PMID: 16564136
   PubMed Web of Science ®Google Scholar
• Sharon N, Ofek I. Safe as mother’s milk: carbohydrates as future anti-adhesion drugs for bacterial diseases. Glycoconj J 2000; 17:659 - 64; http://dx.doi.org/10.1023/A:1011091029973; PMID: 11421356
   PubMed Web of Science ®Google Scholar
• Shoaf-Sweeney KD, Hutkins RW. Adherence, anti-adherence, and oligosaccharides preventing pathogens from sticking to the host. Adv Food Nutr Res 2009; 55:101 - 61; PMID: 18772103
   PubMedGoogle Scholar
• Mulvey G, Kitov PI, Marcato P, Bundle DR, Armstrong GD. Glycan mimicry as a basis for novel anti-infective drugs. Biochimie 2001; 83:841 - 7; http://dx.doi.org/10.1016/S0300-9084(01)01291-3; PMID: 11530217
   PubMed Web of Science ®Google Scholar
• Aronson M, Medalia O, Schori L, Mirelman D, Sharon N, Ofek I. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside. J Infect Dis 1979; 139:329 - 32; http://dx.doi.org/10.1093/infdis/139.3.329; PMID: 376757
   PubMed Web of Science ®Google Scholar
• Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun 1987; 55:472 - 6; PMID: 3542836
   PubMed Web of Science ®Google Scholar
• Almant M, Moreau V, Kovensky J, Bouckaert J, Gouin SG. Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl α-D-mannoside probes with a carbohydrate core. Chemistry 2011; 17:10029 - 38; http://dx.doi.org/10.1002/chem.201100515; PMID: 21774001
   PubMed Web of Science ®Google Scholar
• Schierholt A, Hartmann M, Lindhorst TK. Bi- and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding. Carbohydr Res 2011; 346:1519 - 26; http://dx.doi.org/10.1016/j.carres.2011.04.023; PMID: 21645881
   PubMed Web of Science ®Google Scholar
• Richards SJ, Jones MW, Hunaban M, Haddleton DM, Gibson MI. Probing bacterial-toxin inhibition with synthetic glycopolymers prepared by tandem post-polymerization modification: role of linker length and carbohydrate density. Angew Chem Int Ed Engl 2012; 51:7812 - 6; http://dx.doi.org/10.1002/anie.201202945; PMID: 22715146
   PubMed Web of Science ®Google Scholar
• Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 2010; 53:4779 - 92; http://dx.doi.org/10.1021/jm100438s; PMID: 20507142
   PubMed Web of Science ®Google Scholar
• Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 2012; 55:3945 - 59; http://dx.doi.org/10.1021/jm300165m; PMID: 22449031
   PubMed Web of Science ®Google Scholar
• Scharenberg M, Schwardt O, Rabbani S, Ernst B. Target Selectivity of FimH Antagonists. J Med Chem 2012; 55:9810 - 6; http://dx.doi.org/10.1021/jm3010338; PMID: 23088608
   PubMed Web of Science ®Google Scholar
• Hartmann M, Papavlassopoulos H, Chandrasekaran V, Grabosch C, Beiroth F, Lindhorst TK, et al. Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. FEBS Lett 2012; 586:1459 - 65; http://dx.doi.org/10.1016/j.febslet.2012.03.059; PMID: 22673511
   PubMed Web of Science ®Google Scholar
• Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 2010; 53:8627 - 41; http://dx.doi.org/10.1021/jm101011y; PMID: 21105658
   PubMed Web of Science ®Google Scholar
• Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, et al. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem 2012; 55:4700 - 13; http://dx.doi.org/10.1021/jm300192x; PMID: 22519985
   PubMed Web of Science ®Google Scholar
• Shmuely H, Ofek I, Weiss EI, Rones Z, Houri-Haddad Y. Cranberry components for the therapy of infectious disease. Curr Opin Biotechnol 2012; 23:148 - 52; http://dx.doi.org/10.1016/j.copbio.2011.10.009; PMID: 22088310
   PubMed Web of Science ®Google Scholar
• Labrecque J, Bodet C, Chandad F, Grenier D. Effects of a high-molecular-weight cranberry fraction on growth, biofilm formation and adherence of Porphyromonas gingivalis. J Antimicrob Chemother 2006; 58:439 - 43; http://dx.doi.org/10.1093/jac/dkl220; PMID: 16735419
   PubMed Web of Science ®Google Scholar
• Burger O, Ofek I, Tabak M, Weiss EI, Sharon N, Neeman I. A high molecular mass constituent of cranberry juice inhibits helicobacter pylori adhesion to human gastric mucus. FEMS Immunol Med Microbiol 2000; 29:295 - 301; http://dx.doi.org/10.1111/j.1574-695X.2000.tb01537.x; PMID: 11118911
   PubMed Web of Science ®Google Scholar
• Burger O, Weiss E, Sharon N, Tabak M, Neeman I, Ofek I. Inhibition of Helicobacter pylori adhesion to human gastric mucus by a high-molecular-weight constituent of cranberry juice. Crit Rev Food Sci Nutr 2002; 42:Suppl 279 - 84; http://dx.doi.org/10.1080/10408390209351916; PMID: 12058986
   PubMed Web of Science ®Google Scholar
• Toivanen M, Ryynänen A, Huttunen S, Duricová J, Riihinen K, Törrönen R, et al. Binding of Neisseria meningitidis pili to berry polyphenolic fractions. J Agric Food Chem 2009; 57:3120 - 7; http://dx.doi.org/10.1021/jf803488s; PMID: 19281178
   PubMed Web of Science ®Google Scholar
• O’May C, Tufenkji N. The swarming motility of Pseudomonas aeruginosa is blocked by cranberry proanthocyanidins and other tannin-containing materials. Appl Environ Microbiol 2011; 77:3061 - 7; http://dx.doi.org/10.1128/AEM.02677-10; PMID: 21378043
   PubMed Web of Science ®Google Scholar
• Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol 2002; 9:1558 - 62; PMID: 12121581
   PubMedGoogle Scholar
• Stapleton AE, Dziura J, Hooton TM, Cox ME, Yarova-Yarovaya Y, Chen S, et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc 2012; 87:143 - 50; http://dx.doi.org/10.1016/j.mayocp.2011.10.006; PMID: 22305026
   PubMed Web of Science ®Google Scholar
• Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001; 322:1571; http://dx.doi.org/10.1136/bmj.322.7302.1571; PMID: 11431298
   PubMed Web of Science ®Google Scholar
• Bonetta A, Di Pierro F. Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma. Cancer Manag Res 2012; 4:281 - 6; PMID: 22977312
   PubMedGoogle Scholar
• Signoretto C, Canepari P, Stauder M, Vezzulli L, Pruzzo C. Functional foods and strategies contrasting bacterial adhesion. Curr Opin Biotechnol 2012; 23:160 - 7; http://dx.doi.org/10.1016/j.copbio.2011.08.006; PMID: 21906930
   PubMed Web of Science ®Google Scholar
• Van Klinken BJ, Dekker J, Büller HA, Einerhand AW. Mucin gene structure and expression: protection vs. adhesion. Am J Physiol 1995; 269:G613 - 27; PMID: 7491952
   PubMed Web of Science ®Google Scholar
• Lillehoj EP, Kim BT, Kim KC. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am J Physiol Lung Cell Mol Physiol 2002; 282:L751 - 6; PMID: 11880301
   PubMed Web of Science ®Google Scholar
• Lindén SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog 2009; 5:e1000617; http://dx.doi.org/10.1371/journal.ppat.1000617; PMID: 19816567
   PubMed Web of Science ®Google Scholar
• Parker P, Sando L, Pearson R, Kongsuwan K, Tellam RL, Smith S. Bovine Muc1 inhibits binding of enteric bacteria to Caco-2 cells. Glycoconj J 2010; 27:89 - 97; http://dx.doi.org/10.1007/s10719-009-9269-2; PMID: 19936918
   PubMed Web of Science ®Google Scholar
• Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 2012; 22:1147 - 62; http://dx.doi.org/10.1093/glycob/cws074; PMID: 22513036
   PubMed Web of Science ®Google Scholar
• Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005; 25:37 - 58; http://dx.doi.org/10.1146/annurev.nutr.25.050304.092553; PMID: 16011458
   PubMed Web of Science ®Google Scholar
• Donovan SM, Wang M, Li M, Friedberg I, Schwartz SL, Chapkin RS. Host-microbe interactions in the neonatal intestine: role of human milk oligosaccharides. Adv Nutr 2012; 3:450S - 5S; http://dx.doi.org/10.3945/an.112.001859; PMID: 22585924
   PubMed Web of Science ®Google Scholar
• Simon PM, Goode PL, Mobasseri A, Zopf D. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun 1997; 65:750 - 7; PMID: 9009338
   PubMed Web of Science ®Google Scholar
• Jantscher-Krenn E, Zherebtsov M, Nissan C, Goth K, Guner YS, Naidu N, et al. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. Gut 2012; 61:1417 - 25; http://dx.doi.org/10.1136/gutjnl-2011-301404; PMID: 22138535
   PubMed Web of Science ®Google Scholar
• Thomas RJ. Receptor mimicry as novel therapeutic treatment for biothreat agents. Bioeng Bugs 2010; 1:17 - 30; http://dx.doi.org/10.4161/bbug.1.1.10049; PMID: 21327124
   PubMedGoogle Scholar
• Lee KK, Wong WY, Sheth HB, Hodges RS, Paranchych W, Irvin RT. Use of synthetic peptides in characterization of microbial adhesins. Methods Enzymol 1995; 253:115 - 31; http://dx.doi.org/10.1016/S0076-6879(95)53013-4; PMID: 7476380
   PubMed Web of Science ®Google Scholar
• Yu L, Lee KK, Paranchych W, Hodges RS, Irvin RT. Use of synthetic peptides to confirm that the Pseudomonas aeruginosa PAK pilus adhesin and the Candida albicans fimbrial adhesin possess a homologous receptor-binding domain. Mol Microbiol 1996; 19:1107 - 16; http://dx.doi.org/10.1046/j.1365-2958.1996.454982.x; PMID: 8830267
   PubMed Web of Science ®Google Scholar
• Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD. Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 1990; 61:1375 - 82; http://dx.doi.org/10.1016/0092-8674(90)90701-F; PMID: 2364431
   PubMed Web of Science ®Google Scholar
• Lehner T, Caldwell J, Smith R. Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infect Immun 1985; 50:796 - 9; PMID: 4066030
   PubMed Web of Science ®Google Scholar
• Ma JK, Hunjan M, Smith R, Lehner T. Specificity of monoclonal antibodies in local passive immunization against Streptococcus mutans. Clin Exp Immunol 1989; 77:331 - 7; PMID: 2478321
   PubMed Web of Science ®Google Scholar
• Munro GH, Evans P, Todryk S, Buckett P, Kelly CG, Lehner T. A protein fragment of streptococcal cell surface antigen I/II which prevents adhesion of Streptococcus mutans. Infect Immun 1993; 61:4590 - 8; PMID: 7691754
   PubMed Web of Science ®Google Scholar
• Kelly CG, Younson JS, Hikmat BY, Todryk SM, Czisch M, Haris PI, et al. A synthetic peptide adhesion epitope as a novel antimicrobial agent. Nat Biotechnol 1999; 17:42 - 7; http://dx.doi.org/10.1038/5213; PMID: 9920267
   PubMed Web of Science ®Google Scholar
• Younson J, Kelly C. The rational design of an anti-caries peptide against Streptococcus mutans. Mol Divers 2004; 8:121 - 6; http://dx.doi.org/10.1023/B:MODI.0000025655.93643.fa; PMID: 15209163
   PubMed Web of Science ®Google Scholar
• Krachler AM, Orth K. Functional characterization of the interaction between bacterial adhesin multivalent adhesion molecule 7 (MAM7) protein and its host cell ligands. J Biol Chem 2011; 286:38939 - 47; http://dx.doi.org/10.1074/jbc.M111.291377; PMID: 21937438
   PubMed Web of Science ®Google Scholar
• Krachler AM, Ham H, Orth K. Turnabout is fair play: use of the bacterial Multivalent Adhesion Molecule 7 as an antimicrobial agent. Virulence 2012; 3:68 - 71; http://dx.doi.org/10.4161/viru.3.1.18172; PMID: 22086133
   PubMed Web of Science ®Google Scholar
• Krachler AM, Mende K, Murray C, Orth K. In vitro characterization of multivalent adhesion molecule 7-based inhibition of multidrug-resistant bacteria isolated from wounded military personnel. Virulence 2012; 3:389 - 99; http://dx.doi.org/10.4161/viru.20816; PMID: 22722243
   PubMed Web of Science ®Google Scholar
• Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998; 16:153 - 7; http://dx.doi.org/10.1038/nbt0298-153; PMID: 9487521
   PubMed Web of Science ®Google Scholar
• Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 2007; 4:141 - 51; http://dx.doi.org/10.2174/156720107780362339; PMID: 17456033
   PubMedGoogle Scholar
• Saraogi I, Hamilton AD. Recent advances in the development of aryl-based foldamers. Chem Soc Rev 2009; 38:1726 - 43; http://dx.doi.org/10.1039/b819597h; PMID: 19587965
   PubMed Web of Science ®Google Scholar
• Liskamp RM, Rijkers DT, Kruijtzer JA, Kemmink J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. Chembiochem 2011; 12:1626 - 53; http://dx.doi.org/10.1002/cbic.201000717; PMID: 21751324
   PubMed Web of Science ®Google Scholar
• Eucker TP, Konkel ME. The cooperative action of bacterial fibronectin-binding proteins and secreted proteins promote maximal Campylobacter jejuni invasion of host cells by stimulating membrane ruffling. Cell Microbiol 2012; 14:226 - 38; http://dx.doi.org/10.1111/j.1462-5822.2011.01714.x; PMID: 21999233
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al, TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175 - 85; http://dx.doi.org/10.1056/NEJMoa035026; PMID: 12637625
   PubMed Web of Science ®Google Scholar
• Ghosh S, Chakraborty K, Nagaraja T, Basak S, Koley H, Dutta S, et al. An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development. Proc Natl Acad Sci U S A 2011; 108:3348 - 53; http://dx.doi.org/10.1073/pnas.1016180108; PMID: 21300870
   PubMed Web of Science ®Google Scholar
• Wagner C, Hensel M. Adhesive mechanisms of Salmonella enterica. Adv Exp Med Biol 2011; 715:17 - 34; http://dx.doi.org/10.1007/978-94-007-0940-9_2; PMID: 21557055
   PubMed Web of Science ®Google Scholar
• Bravo D, Blondel CJ, Hoare A, Leyton L, Valvano MA, Contreras I. Type IV(B) pili are required for invasion but not for adhesion of Salmonella enterica serovar Typhi into BHK epithelial cells in a cystic fibrosis transmembrane conductance regulator-independent manner. Microb Pathog 2011; 51:373 - 7; http://dx.doi.org/10.1016/j.micpath.2011.07.005; PMID: 21782926
   PubMed Web of Science ®Google Scholar
• Raghunathan D, Wells TJ, Morris FC, Shaw RK, Bobat S, Peters SE, et al. SadA, a trimeric autotransporter from Salmonella enterica serovar Typhimurium, can promote biofilm formation and provides limited protection against infection. Infect Immun 2011; 79:4342 - 52; http://dx.doi.org/10.1128/IAI.05592-11; PMID: 21859856
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang W. Escherichia coli K88ac fimbriae expressing heat-labile and heat-stable (STa) toxin epitopes elicit antibodies that neutralize cholera toxin and STa toxin and inhibit adherence of K88ac fimbrial E. coli. Clin Vaccine Immunol 2010; 17:1859 - 67; http://dx.doi.org/10.1128/CVI.00251-10; PMID: 20980482
   PubMed Web of Science ®Google Scholar
• Gao X, Cai K, Li T, Wang Q, Hou X, Tian R, et al. Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice. Vaccine 2011; 29:6656 - 63; http://dx.doi.org/10.1016/j.vaccine.2011.06.106; PMID: 21742003
   PubMed Web of Science ®Google Scholar
• Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997; 276:607 - 11; http://dx.doi.org/10.1126/science.276.5312.607; PMID: 9110982
   PubMed Web of Science ®Google Scholar
• Langermann S, Möllby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000; 181:774 - 8; http://dx.doi.org/10.1086/315258; PMID: 10669375
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J 2013; 24:127 - 34; http://dx.doi.org/10.1007/s00192-012-1853-5; PMID: 22806485
   PubMed Web of Science ®Google Scholar
• Cachia PJ, Hodges RS. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Biopolymers 2003; 71:141 - 68; http://dx.doi.org/10.1002/bip.10395; PMID: 12767116
   PubMed Web of Science ®Google Scholar
• Sheth HB, Glasier LM, Ellert NW, Cachia P, Kohn W, Lee KK, et al. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Biomed Pept Proteins Nucleic Acids 1995; 1:141 - 8; PMID: 9346845
   PubMedGoogle Scholar
• Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30:Suppl 2 B87 - 97; http://dx.doi.org/10.1016/j.vaccine.2012.01.033; PMID: 22607904
   PubMed Web of Science ®Google Scholar
• Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011; 10:575 - 88; http://dx.doi.org/10.1586/erv.11.32; PMID: 21604979
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127 - 37; http://dx.doi.org/10.1086/656741; PMID: 20954968
   PubMed Web of Science ®Google Scholar
• Carleton HA. Pathogenic bacteria as vaccine vectors: teaching old bugs new tricks. Yale J Biol Med 2010; 83:217 - 22; PMID: 21165341
   PubMedGoogle Scholar
• Hur J, Stein BD, Lee JH. A vaccine candidate for post-weaning diarrhea in swine constructed with a live attenuated Salmonella delivering Escherichia coli K88ab, K88ac, FedA, and FedF fimbrial antigens and its immune responses in a murine model. Can J Vet Res 2012; 76:186 - 94; PMID: 23277697
   PubMed Web of Science ®Google Scholar
• Hur J, Lee JH. Development of a novel live vaccine delivering enterotoxigenic Escherichia coli fimbrial antigens to prevent post-weaning diarrhea in piglets. Vet Immunol Immunopathol 2012; 146:283 - 8; http://dx.doi.org/10.1016/j.vetimm.2012.02.002; PMID: 22417986
   PubMed Web of Science ®Google Scholar
• Frey J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine 2007; 25:5598 - 605; http://dx.doi.org/10.1016/j.vaccine.2006.11.058; PMID: 17239999
   PubMed Web of Science ®Google Scholar
• Arciola CR, Speziale P, Montanaro L. Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections. Int J Artif Organs 2009; 32:635 - 41; PMID: 19882551
   PubMed Web of Science ®Google Scholar
• Therrien R, Lacasse P, Grondin G, Talbot BG. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 2007; 25:5053 - 61; http://dx.doi.org/10.1016/j.vaccine.2007.04.067; PMID: 17532546
   PubMed Web of Science ®Google Scholar
• Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus. Vaccine 2007; 25:814 - 24; http://dx.doi.org/10.1016/j.vaccine.2006.09.043; PMID: 17027124
   PubMed Web of Science ®Google Scholar
• Ofek I, Hasty DL, Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 2003; 38:181 - 91; http://dx.doi.org/10.1016/S0928-8244(03)00228-1; PMID: 14522453
   PubMed Web of Science ®Google Scholar
• Wizemann TM, Adamou JE, Langermann S. Adhesins as targets for vaccine development. Emerg Infect Dis 1999; 5:395 - 403; http://dx.doi.org/10.3201/eid0503.990310; PMID: 10341176
   PubMed Web of Science ®Google Scholar
• Sokurenko EV, Chesnokova V, Dykhuizen DE, Ofek I, Wu XR, Krogfelt KA, et al. Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin. Proc Natl Acad Sci U S A 1998; 95:8922 - 6; http://dx.doi.org/10.1073/pnas.95.15.8922; PMID: 9671780
   PubMed Web of Science ®Google Scholar
• Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?. J Antimicrob Chemother 2009; 63:238 - 42; http://dx.doi.org/10.1093/jac/dkn477; PMID: 19028718
   PubMed Web of Science ®Google Scholar
• Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 2001; 13:Spec No 1 159 - 72; PMID: 11936361
   PubMed Web of Science ®Google Scholar
• Rogers TJ, Paton JC. Therapeutic strategies for Shiga toxin-producing Escherichia coli infections. Expert Rev Anti Infect Ther 2009; 7:683 - 6; http://dx.doi.org/10.1586/eri.09.51; PMID: 19681694
   PubMedGoogle Scholar
• Mintzer MA, Dane EL, O’Toole GA, Grinstaff MW. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm 2012; 9:342 - 54; http://dx.doi.org/10.1021/mp2005033; PMID: 22126461
   PubMed Web of Science ®Google Scholar
• Tseng YT, Chang HT, Chen CT, Chen CH, Huang CC. Preparation of highly luminescent mannose-gold nanodots for detection and inhibition of growth of Escherichia coli. Biosens Bioelectron 2011; 27:95 - 100; http://dx.doi.org/10.1016/j.bios.2011.06.021; PMID: 21757332
   PubMed Web of Science ®Google Scholar
• Durka M, Buffet K, Iehl J, Holler M, Nierengarten JF, Taganna J, et al. The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH--towards novel bacterial antiadhesives. Chem Commun (Camb) 2011; 47:1321 - 3; http://dx.doi.org/10.1039/c0cc04468g; PMID: 21103505
   PubMed Web of Science ®Google Scholar
• Schengrund CL. “Multivalent” saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem Pharmacol 2003; 65:699 - 707; http://dx.doi.org/10.1016/S0006-2952(02)01553-8; PMID: 12628483
   PubMed Web of Science ®Google Scholar
• Pieters RJ. Intervention with bacterial adhesion by multivalent carbohydrates. Med Res Rev 2007; 27:796 - 816; http://dx.doi.org/10.1002/med.20089; PMID: 17022032
   PubMed Web of Science ®Google Scholar
• Pieters RJ. Maximising multivalency effects in protein-carbohydrate interactions. Org Biomol Chem 2009; 7:2013 - 25; http://dx.doi.org/10.1039/b901828j; PMID: 19421435
   PubMed Web of Science ®Google Scholar
• Endo T, Koizumi S. Large-scale production of oligosaccharides using engineered bacteria. Curr Opin Struct Biol 2000; 10:536 - 41; http://dx.doi.org/10.1016/S0959-440X(00)00127-5; PMID: 11042450
   PubMed Web of Science ®Google Scholar
• Hyun H, Yui N. Ligand accessibility to receptor binding sites enhanced by movable polyrotaxanes. Macromol Biosci 2011; 11:765 - 71; http://dx.doi.org/10.1002/mabi.201000507; PMID: 21384556
   PubMed Web of Science ®Google Scholar
• Kim J, Ahn Y, Park KM, Lee DW, Kim K. Glyco-pseudopolyrotaxanes: carbohydrate wheels threaded on a polymer string and their inhibition of bacterial adhesion. Chemistry 2010; 16:12168 - 73; http://dx.doi.org/10.1002/chem.201001538; PMID: 20859967
   PubMed Web of Science ®Google Scholar
• Bricarello DA, Patel MA, Parikh AN. Inhibiting host-pathogen interactions using membrane-based nanostructures. Trends Biotechnol 2012; 30:323 - 30; http://dx.doi.org/10.1016/j.tibtech.2012.03.002; PMID: 22464596
   PubMed Web of Science ®Google Scholar
• Bricarello DA, Mills EJ, Petrlova J, Voss JC, Parikh AN. Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinity. J Lipid Res 2010; 51:2731 - 8; http://dx.doi.org/10.1194/jlr.M007401; PMID: 20472870
   PubMed Web of Science ®Google Scholar
• Shi J, Yang T, Kataoka S, Zhang Y, Diaz AJ, Cremer PS. GM1 clustering inhibits cholera toxin binding in supported phospholipid membranes. J Am Chem Soc 2007; 129:5954 - 61; http://dx.doi.org/10.1021/ja069375w; PMID: 17429973
   PubMed Web of Science ®Google Scholar
• Paton AW, Morona R, Paton JC. Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 2006; 4:193 - 200; http://dx.doi.org/10.1038/nrmicro1349; PMID: 16462752
   PubMed Web of Science ®Google Scholar
• Khani S, Hosseini HM, Taheri M, Nourani MR, Imani Fooladi AA. Probiotics as an alternative strategy for prevention and treatment of human diseases: a review. Inflamm Allergy Drug Targets 2012; 11:79 - 89; http://dx.doi.org/10.2174/187152812800392832; PMID: 22280243
   PubMedGoogle Scholar
• Jeppsson B, Mangell P, Thorlacius H. Use of probiotics as prophylaxis for postoperative infections. Nutrients 2011; 3:604 - 12; http://dx.doi.org/10.3390/nu3050604; PMID: 22254113
   PubMedGoogle Scholar
• Ghareeb K, Awad WA, Mohnl M, Porta R, Biarnés M, Böhm J, et al. Evaluating the efficacy of an avian-specific probiotic to reduce the colonization of Campylobacter jejuni in broiler chickens. Poult Sci 2012; 91:1825 - 32; http://dx.doi.org/10.3382/ps.2012-02168; PMID: 22802174
   PubMed Web of Science ®Google Scholar
• Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002; 32:105 - 10; http://dx.doi.org/10.1111/j.1574-695X.2002.tb00541.x; PMID: 11821231
   PubMed Web of Science ®Google Scholar
• Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 2003; 17:741 - 54; http://dx.doi.org/10.1016/S1521-6918(03)00052-0; PMID: 14507585
   PubMed Web of Science ®Google Scholar
• Campana R, Federici S, Ciandrini E, Baffone W. Antagonistic activity of Lactobacillus acidophilus ATCC 4356 on the growth and adhesion/invasion characteristics of human Campylobacter jejuni. Curr Microbiol 2012; 64:371 - 8; http://dx.doi.org/10.1007/s00284-012-0080-0; PMID: 22271268
   PubMed Web of Science ®Google Scholar
• Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6:265 - 70; http://dx.doi.org/10.1038/73111; PMID: 10700227
   PubMed Web of Science ®Google Scholar
• Paton AW, Jennings MP, Morona R, Wang H, Focareta A, Roddam LF, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005; 128:1219 - 28; http://dx.doi.org/10.1053/j.gastro.2005.01.050; PMID: 15887106
   PubMed Web of Science ®Google Scholar
• Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006; 130:1688 - 95; http://dx.doi.org/10.1053/j.gastro.2006.02.005; PMID: 16697733
   PubMed Web of Science ®Google Scholar
• Pinyon RA, Paton JC, Paton AW, Botten JA, Morona R. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis 2004; 189:1547 - 55; http://dx.doi.org/10.1086/383417; PMID: 15116289
   PubMed Web of Science ®Google Scholar
• Paton AW, Morona R, Paton JC. Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections. Bioeng Bugs 2010; 1:172 - 7; http://dx.doi.org/10.4161/bbug.1.3.10665; PMID: 21326923
   PubMedGoogle Scholar
• Gustke H, Kleene R, Loers G, Nehmann N, Jaehne M, Bartels KM, et al. Inhibition of the bacterial lectins of Pseudomonas aeruginosa with monosaccharides and peptides. Eur J Clin Microbiol Infect Dis 2012; 31:207 - 15; http://dx.doi.org/10.1007/s10096-011-1295-x; PMID: 21604096
   PubMed Web of Science ®Google Scholar
• Otto K. Biophysical approaches to study the dynamic process of bacterial adhesion. Res Microbiol 2008; 159:415 - 22; http://dx.doi.org/10.1016/j.resmic.2008.04.007; PMID: 18550342
   PubMed Web of Science ®Google Scholar
• Mascari L, Ymele-Leki P, Eggleton CD, Speziale P, Ross JM. Fluid shear contributions to bacteria cell detachment initiated by a monoclonal antibody. Biotechnol Bioeng 2003; 83:65 - 74; http://dx.doi.org/10.1002/bit.10650; PMID: 12740934
   PubMed Web of Science ®Google Scholar
• Klinth JE, Pinkner JS, Hultgren SJ, Almqvist F, Uhlin BE, Axner O. Impairment of the biomechanical compliance of P pili: a novel means of inhibiting uropathogenic bacterial infections?. Eur Biophys J 2012; 41:285 - 95; http://dx.doi.org/10.1007/s00249-011-0784-2; PMID: 22237603
   PubMed Web of Science ®Google Scholar